Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of combining atezolizumab, a humanized monoclonal anti–PD-L1 antibody, with venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia (CLL). This regimen has shown high measurable residual disease (MRD)-negative remission rates in a Phase II study of 37 patients (NCT02846623), with some expected immune toxicity observed. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.